Last reviewed · How we verify
NCT06348511
XTics - A Gamified Enhancer of Non-Pharmacological Interventions in Tic Disorders
NA trial testing XTics in Tic Disorders in 35 participants. Completed in 31 December 2022.
31 December 2022
Quick facts
| Lead sponsor | Tel-Aviv Sourasky Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 35 |
| Start date | 1 July 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- XTics
Conditions studied
- Tic Disorders — all drugs for Tic Disorders →
Sponsor
Tel-Aviv Sourasky Medical Center
Who can join
Adults 7 to 15, any sex, with Tic Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators developed a neuroscientifically-informed gamified tic-therapy platform. The investigators previously identified tic-triggering elements in movies and video games. Next, the investigators employed these elements to generate and validate a gamified intervention protocol, which is based on a video game the investigators designed (called XTics). The study tests the efficacy of the gamified tool integrated in an exposure and response prevention (ERP) protocol to enhance both patient's compliance and clinical outcome.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06348511
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tic Disorders
Currently open trials in the same condition.
- NCT07351955 — Clinical Study on a Novel Strategy of Individualized Non-Invasive Neuromodulation for the Treatment of Tic Disorders in · NA · recruiting
- NCT06679790 — Trajectories of Change in Tourette Syndrome · NA · recruiting
- NCT06050369 — Objective Characterizatoion of Repetitive Behaviors · NA · recruiting
- NCT05370391 — Comprehensive Behavioral Intervention for Tics · NA · recruiting
- NCT05317390 — Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia · NA · recruiting
Other Tel-Aviv Sourasky Medical Center trials
Trials by the same sponsor.
- NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
- NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06348511 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
- Last refreshed: 4 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06348511.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing